Research · Sep 3, 2026
[RVMD] Revolution Medicines Thesis 2026: RAS Inhibitor Pipeline Tests Pancreatic Cancer Readouts
Revolution Medicines Inc. (NASDAQ: RVMD) FY2025 revenue ~$5-15M (selected pre-commercial; primarily collaboration revenue) with diluted EPS ~-$5.00 to -$4.20 reflecting continued ~$1.0-1.2B annual R&D spend supporting selected ~10+ active RAS(ON) inhibitor pipeline candidates including Daraxonrasib (RMC-6236; pan-RAS multi-selective inhibitor) + RMC-6291 (KRAS G12C(ON) inhibitor) + RMC-9805 (KRAS G12D(ON) inhibitor) + selected various RAS pipeline + selected post-2024 RASolute 302 Phase 3 pivotal trial (Daraxonrasib KRAS G12X mutated metastatic pancreatic ductal adenocarcinoma) under continued President + CEO Mark Goldsmith (~11-year tenure since 2014 founding). Clinical-stage oncology biotech focused on RAS-MAPK pathway inhibitors with operations across selected US R&D + selected various. Founded 2014 in Redwood City California by Mark Goldsmith + Rich Heyman (~11-year heritage); selected post-February 2020 NASDAQ IPO (~$238M raised); selected post-2020 ~$500M aggregate Sanofi collaboration (RMC-4630 SHP2 inhibitor; subsequently terminated 2022); selected post-2021 RAS(ON) inhibitor portfolio focus; selected post-2024 RASolute 302 Phase 3 pivotal trial enrollment. Headquartered in Redwood City California; ~600+ employees globally with ~$5-15M revenue. Single primary product franchise structure: clinical-stage RAS-MAPK pathway oncology pipeline. RAS inhibitor pipeline leadership: ~10+ active RAS pipeline including Daraxonrasib (RMC-6236; pan-RAS multi-selective inhibitor; selected lead asset) + RMC-6291 (KRAS G12C(ON) inhibitor; differentiated vs Mirati's adagrasib + Amgen's sotorasib) + RMC-9805 (KRAS G12D(ON) inhibitor; first-in-class) + selected various RAS-MAPK pathway inhibitors; selected primary indications pancreatic + lung + colorectal cancers. Daraxonrasib RASolute 302 Phase 3 readout: post-2024 RASolute 302 Phase 3 pivotal trial enrollment completion (Daraxonrasib monotherapy vs chemotherapy in 2L KRAS G12X mutated metastatic PDAC); selected initial readout expected H1 2026; selected potential post-2026 first US FDA approval submission; ~$3-5B+ peak sales potential. R&D + cash position: ~$1.0-1.2B aggregate annual R&D supporting ~10+ active pivotal trials; ~$2.0-2.4B aggregate cash + investments FY2025; selected ~24-30 month aggregate cash runway; selected post-2024 ~$1B+ aggregate equity raises. President + CEO Mark Goldsmith since 2014 founding (~11-year tenure); CFO Jack Anders. Capital structure: ~$2.0-2.4B aggregate cash + investments; no dividend; no buybacks (capital priority on growth + R&D investment); ~$1.0-1.2B annual R&D spend; selected continued cash burn FCF margin negative; investment-grade Caa1/CCC+ credit rating. FY2026 thesis: RASolute 302 Phase 3 readout + Daraxonrasib RAS-MAPK pathway leadership + selected various pipeline progression + selected potential commercial inflection FY2027 + selected various indication expansion. Risks: RASolute 302 Phase 3 failure, Mirati Therapeutics + Amgen + Bristol-Myers Squibb RAS competition, ~$1.0-1.2B annual R&D cash burn, ~10+ active pipeline trial execution, currency.